Aligos Therapeutics, Modified Gapmer Oligonucleotides and Methods of Use, EP3976056A2
Summary
The European Patent Office published patent application EP3976056A2 on April 15, 2026, disclosing modified gapmer oligonucleotides and methods of use invented by Aligos Therapeutics, Inc. The patent application covers therapeutic applications for gapmer oligonucleotides, with A61K31/7088, C12N15/113, and A61P31/20 IPC classifications. The application designates all EU member states plus several other countries including CH, GB, NO, TR, and MC.
About this source
GovPing monitors EPO Patent Bulletin - Biotech (C12N) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 53 changes logged to date.
What changed
The EPO published patent application EP3976056A2 for Aligos Therapeutics, Inc., covering modified gapmer oligonucleotides and their use in therapeutic applications. The application includes five named inventors and designates all EU member states plus several other jurisdictions. This publication establishes a priority date for the invention and initiates the examination process under European patent law.
For companies developing oligonucleotide-based therapeutics, this publication signals Aligos Therapeutics' intellectual property position in the gapmer oligonucleotide space. Competitors should review the claims upon publication of the full specification to assess potential freedom-to-operate implications for their own therapeutic programs.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
MODIFIED GAPMER OLIGONUCLEOTIDES AND METHODS OF USE
Publication EP3976056A2 Kind: A2 Apr 15, 2026
Applicants
Aligos Therapeutics, Inc.
Inventors
BEIGELMAN, Leonid, PANDEY, Rajendra K., RAJWANSHI, Vivek Kumar, SMITH, David Bernard, HONG, Jin
IPC Classifications
A61K 31/7088 20060101AFI20220103BHEP C12N 15/113 20100101ALI20220103BHEP A61P 31/20 20060101ALI20220103BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Parties
Related changes
Get daily alerts for EPO Patent Bulletin - Biotech (C12N)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when EPO Patent Bulletin - Biotech (C12N) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.